ASCENTAGE PHARMA GROUP INTERNATIONAL Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Ascentage Pharma performed this year. My goal is to break down their complex financial filings so you can decide if this company fits your investment goals.

1. What does this company do?

Ascentage Pharma is a biotech company developing new cancer therapies. They focus on "small-molecule" drugs that help the body’s natural process of killing off cancer cells. Their two main drugs are Olverembatinib, used for leukemia, and Lisaftoclax. They fund their research by running global clinical trials and by licensing their technology to other companies. They also sell approved products in China.

2. Financial Health: The "Burn" Phase

Ascentage is not yet profitable. They are in a "cash burn" phase, meaning they spend much more than they earn to fund research and operations.

• The Bottom Line: The company lost RMB 1,243 million (about $177.7 million) in 2025, compared to a loss of RMB 405.7 million in 2024. This increase in spending reflects the costs of running global clinical trials, expanding their research team, and managing their dual-listing status.
• Revenue Trends: They brought in RMB 574.1 million ($82.1 million) this year, compared to RMB 980.7 million in 2024. Revenue for biotech companies like this can be unpredictable, as it often relies on one-time licensing payments from partners alongside steady sales of their leukemia drug in China.
• Cash on Hand: They held RMB 2,470.1 million ($353.2 million) at the end of 2025. This provides enough runway to operate for at least the next 12 months. Eventually, the company may need to raise more capital through equity or debt, which could dilute the value of current shares.

3. Major Wins and Challenges

The biggest milestone this year was listing on the Nasdaq (symbol: AAPG). This move helps them reach a broader pool of international investors. However, it also brings them under the direct oversight of U.S. regulators. The company is now more sensitive to trade and regulatory tensions between the U.S. and China, which can influence how they share research data and conduct international clinical trials.

4. Key Risks: What could go wrong?

Investing here is a bet on scientific success. Keep these risks in mind:

• The "Trial" Trap: If a clinical trial fails to show that a drug is safe or effective, the company’s value can drop sharply. There is no guarantee a drug will reach the market, and the cost of failure is high.
• Regulatory Hurdles: They must navigate complex approval processes in both the U.S. and China. If they fail to secure regulatory approval, they cannot recover the massive costs spent on research and development.
• Geopolitical Tension: Because they operate in both the U.S. and China, they are vulnerable to political shifts. If U.S. regulators cannot inspect their Chinese auditors, the company could face delisting from the Nasdaq, which would significantly impact liquidity and share price.

5. The Bottom Line

Ascentage is a "high-risk, high-reward" investment. They have enough cash to fund their operations for the next year, but their losses are growing as they invest heavily in clinical trials. They are still in the process of proving they can turn their scientific pipeline into a sustainable, profitable business.

Decision Tip: Before investing, ask yourself if you are comfortable with the volatility that comes with biotech clinical trials. If you are looking for a stable, dividend-paying company, this is likely not the right fit. If you are interested in the potential of breakthrough cancer treatments and can handle significant price swings, this company warrants a closer look at their upcoming trial results.